Eli Lilly's Obesity Pill Shows Promising Weight Loss but Shares Fall
Originally Published 5 months ago — by Financial Times
Eli Lilly's obesity drug underperformed in clinical trials, leading to a 14% drop in its shares, disappointing investors and raising concerns about its future prospects.